Answers are grounded in this paper and cite their sources.
The introduction of tyrosine kinase inhibitors and immune checkpoint inhibitors considerably improved the treatment of many hematological malignancies. However, these new classes of drugs are associated with novel hitherto not observed endocrine-related adverse effects. Therefore, this review aims to get insight into the pathogenesis of endocrine-related AEs and summarize their management according to the current European recommendations.
No takes yet. Share an insight, caveat, or question.
Bobrowicz et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: